SCHEMBL22098181

SCHEMBL22098181

CC(C)COC(=O)/C=C/c1cccc(CO)c1F

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 3/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ KMT2A Q03164 5/20 0.38
▸ MEN1 O00255 4/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ TSHR P16473 2/20 0.37
▸ LMNA P02545 4/20 0.36
▸ MAPT P10636 1/20 0.36
▸ L3MBTL1 Q9Y468 3/20 0.36
▸ ALOX5 P09917 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ MAP3K7 O43318 1/20 0.34
▸ TAB1 Q15750 1/20 0.34
▸ PTGS2 P35354 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22071109 0.76 EGFR (0.51) KDM4EMAPT
SCHEMBL17482121 0.75 MAPT (0.54) HPGDALDH1A1KDM4EGAATSHR
SCHEMBL28658531 0.75 ALDH1A1 (0.47) HPGDALDH1A1KMT2AMEN1KDM4E
SCHEMBL28658533 0.75 ALDH1A1 (0.47) HPGDALDH1A1KMT2AMEN1KDM4E
SCHEMBL9744921 0.74 AKR1B10 (0.46) HPGDALDH1A1KMT2AKDM4EGAA
SCHEMBL20475031 0.73 NFE2L2 (0.61) HPGDALDH1A1KMT2AMEN1KDM4E
SCHEMBL27382286 0.73 CA12 (0.43) KMT2AMEN1KDM4ELMNAMAPT
SCHEMBL30967858 0.73 CA12 (0.43) KMT2AMEN1KDM4ELMNAMAPT
SCHEMBL31065933 0.71 CA12 (0.48) HPGDALDH1A1KMT2AMEN1KDM4E
SCHEMBL19842227 0.71 ALDH1A1 (0.40) HPGDALDH1A1KMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365192-B2 Pyridine compound substituted with azole TAISHO PHARMACEUTICAL CO., LTD. (JP) 2022-06-21 — — US disclosed
US-11365192-B2 Pyridine compound substituted with azole TAISHO PHARMACEUTICAL CO., LTD. (JP) 2022-06-21 — — US disclosed
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE TAISHO PHARMACEUTICAL CO., LTD (JP) 2021-04-29 — — US disclosed
EP-3666766-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE Taisho Pharmaceutical Co., Ltd. (JP) 2020-06-17 — — EP disclosed
CN-110914254-A Azole-substituted pyridine compound 大正制药株式会社 2020-03-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE CYP2C19, CYP4A11, CYP11B1 HPGD 66/4885ALDH1A1 378/4885KMT2A 813/4885
US-11365192-B2 Pyridine compound substituted with azole CYP2C19, CYP4A11, CYP11B1 HPGD 66/4885ALDH1A1 378/4885KMT2A 813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback